Dave Utriainen

SpinTech continues to extend the boundaries of MRI and recently earned FDA clearance for STAGE, a rapid, quantitative multi-contrast imaging software that integrates seamlessly into existing clinical workflows. STAGE includes the world’s first FDA cleared QSM output and can be used across a wide range of neurodegenerative disorders such as stroke, Multiple Sclerosis, Parkinson’s, traumatic brain injury, dementia, and tumor imaging. In addition, SpinTech offers automated CMB and Parkinson’s Reports that run on top of STAGE data to aid clinicians in detecting microbleeds and quantifying neuromelanin content, respectively.